PLGA microsphere/PVA hydrogel coatings suppress the foreign body reaction for 6 months

&NA; The application of dexamethasone releasing poly (lactic‐co‐glycolic acid) (PLGA) microspheres embedded in a poly vinyl alcohol (PVA) hydrogel coatings have been successfully used in the suppression of the foreign body response (FBR) to implantable glucose sensors. In the current study, dexamethasone‐loaded PLGA microspheres were prepared by blending two types of PLGA polymers (RG503H and DLG7E with MW of ca. 25 kDa and 113 kDa, respectively) to achieve long‐term (6 months) inhibition of the FBR. The microsphere composition was optimized according to the in vitro drug release profiles. Microspheres with DLG7E/RG503H/dexamethasone = 70/13.3/16.7 wt% composition, when embedded in a PVA hydrogel, provided a continuous drug release for 6 months. By combining the aforementioned microspheres with microspheres composed solely of the DLG7E polymer within a similar PVA hydrogel realized an even longer (>7 months) in vitro drug release. A heat map was constructed to depict the daily in vitro drug released and elucidate possible lag phases that could affect the pharmacodynamic response. These drug‐loaded implant coatings were investigated in vivo (rat model) and showed inhibition of the foreign body response for 6 months. These results suggest that the minimum effective daily dose to counter chronic inflammation is ca. 0.1 &mgr;g per mg of coating surrounding a 0.5 × 0.5 × 5 mm silicon implant (dummy sensor). Accordingly, these drug‐eluting composite coatings can ensure long‐term inflammation control for miniaturized implantable devices.

[1]  D. Burgess,et al.  In vitro and in vivo performance of dexamethasone loaded PLGA microspheres prepared using polymer blends. , 2015, International journal of pharmaceutics.

[2]  N. Jeandidier,et al.  French multicentre experience of implantable insulin pumps , 1994, The Lancet.

[3]  Bruce Klitzman,et al.  Porous, Dexamethasone-loaded polyurethane coatings extend performance window of implantable glucose sensors in vivo. , 2016, Acta biomaterialia.

[4]  N. Jeandidier,et al.  High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  Pauline E. Leary,et al.  Elevated temperature accelerated release testing of PLGA microspheres. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Diane J. Burgess,et al.  Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  F. Papadimitrakopoulos,et al.  Multiple tissue response modifiers to promote angiogenesis and prevent the foreign body reaction around subcutaneous implants. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[8]  W. Reichert,et al.  Characterization of porous, dexamethasone-releasing polyurethane coatings for glucose sensors. , 2014, Acta biomaterialia.

[9]  E. A. Vaughn,et al.  The kinetics of peritoneal insulin absorption. , 1981, Metabolism: clinical and experimental.

[10]  J. Vane,et al.  Mechanism of action of anti-inflammatory drugs. , 1997, Advances in experimental medicine and biology.

[11]  F. Papadimitrakopoulos,et al.  Drug Distribution in Microspheres Enhances Their Anti-Inflammatory Properties in the Gottingen Minipig. , 2015, Molecular pharmaceutics.

[12]  Diane J Burgess,et al.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  H. Tabandeh,et al.  DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS , 2011, Retina.

[14]  Shaoyi Jiang,et al.  Zwitterionic poly(carboxybetaine) hydrogels for glucose biosensors in complex media. , 2011, Biosensors & bioelectronics.

[15]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[16]  Fotios Papadimitrakopoulos,et al.  Biomaterials/Tissue Interactions: Possible Solutions to Overcome Foreign Body Response , 2010, The AAPS Journal.

[17]  Michael O'Grady,et al.  Continuous glucose monitoring and intensive treatment of type 1 diabetes. , 2008, The New England journal of medicine.

[18]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[19]  Fotios Papadimitrakopoulos,et al.  Controlling Acute Inflammation with Fast Releasing Dexamethasone-PLGA Microsphere/PVA Hydrogel Composites for Implantable Devices , 2007, Journal of diabetes science and technology.

[20]  Fotios Papadimitrakopoulos,et al.  PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. , 2010, International journal of pharmaceutics.

[21]  Fotios Papadimitrakopoulos,et al.  Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels , 2005, The AAPS Journal.

[22]  F. Papadimitrakopoulos,et al.  Prevention of foreign body reaction in a pre-clinical large animal model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Lutz Heinemann,et al.  Finger Pricking and Pain: A Never Ending Story , 2008, Journal of diabetes science and technology.

[24]  Diane J Burgess,et al.  Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach. , 2015, International journal of pharmaceutics.

[25]  Xiao-Yan Li,et al.  Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[26]  Yan Wang,et al.  Polymeric "smart" coatings to prevent foreign body response to implantable biosensors. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[27]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[28]  F. Papadimitrakopoulos,et al.  Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. , 2004, Diabetes technology & therapeutics.

[29]  S. Gupta,et al.  Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. , 2013, Ophthalmology.

[30]  Santhisagar Vaddiraju,et al.  Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises , 2010, Journal of diabetes science and technology.

[31]  T Tschernig,et al.  Locally applied macrophage-activating lipopeptide-2 (MALP-2) promotes early vascularization of implanted porous polyethylene (Medpor®). , 2014, Acta biomaterialia.

[32]  A. Vestri,et al.  Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema , 2013, Clinical ophthalmology.

[33]  James M. Anderson,et al.  Foreign body reaction to biomaterials. , 2008, Seminars in immunology.

[34]  R. Wredling,et al.  Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. , 1991, Diabete & metabolisme.

[35]  Neil Mulholland.  Porous , 2019, Re-imagining the Art School.